A randomised controlled trial of oral l-arginine supplementation on platelet and endothelial function and walking distance in patients with peripheral arterial disease - L-ARGININE IN PAD

Phase 1

• Conditions: Peripheral arterial disease

• Registration Number: EUCTR2006-001125-26-GB
• Lead Sponsor: niversity of Aberdeen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-07-23
• Study Completion: 2006-12-29
• Last Update Posted: 27 July 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

All patients must be able to give informed consent, have an ABPI<0.8 and be on a statin and aspirin. If patients are not on these medications they will be commenced and enrolled 6 weeks later. We wish to determine the adjuvant effects of L-arginine in patients with PAD on what is considered to be routine medical therapy. All patients in this study will attend our nurse led claudication clinic and strict attention will be paid to secondary risk factor prevention as per our local guidelines.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients with rest pain or ulceration, liver impairment or abnormal platelet count or diabetes and those on clopidogrel, warfarin or non-steroidal anti-inflammatory drugs other than aspirin.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified